The role of inflammation in head and neck cancer

M Bonomi, A Patsias, M Posner, A Sikora - Inflammation and cancer, 2014 - Springer
Cancer-related inflammation is considered the “seventh hallmark of cancer”; numerous
studies demonstrate that tumors develop and progress within inflammatory diseases …

Molecular markers for cancer prognosis and treatment: have we struck gold?

S Nowsheen, K Aziz, MI Panayiotidis, AG Georgakilas - Cancer letters, 2012 - Elsevier
The last decade has witnessed an emerging role for molecular or biochemical markers
indicating a specific cellular mechanism or tissue function, often called 'biomarkers' …

Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer

A Kirane, JE Toombs, K Ostapoff, JG Carbon… - Clinical Cancer …, 2012 - AACR
Purpose: COX-2 is expressed highly in pancreatic cancer and implicated in tumor
progression. COX-2 inhibition can reduce tumor growth and augment therapy. The precise …

Randomized phase 2 trial of erlotinib in combination with high‐dose celecoxib or placebo in patients with advanced non‐small cell lung cancer

KL Reckamp, M Koczywas, MC Cristea, JE Dowell… - Cancer, 2015 - Wiley Online Library
BACKGROUND Cyclooxygenase 2 (COX‐2)‐dependent signaling represents a potential
mechanism of resistance to therapy with epidermal growth factor receptor (EGFR) tyrosine …

[图书][B] Lipidomics: technologies and applications

K Ekroos - 2012 - books.google.com
Focusing on the practical applications, this user-oriented guide presents current
technologies and strategies for systems-level lipid analysis, going beyond basic research to …

Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts

X Wang, L Zhang, A O'neill, B Bahamon… - British journal of …, 2013 - nature.com
Background: Sunitinib (Su), a tyrosine kinase inhibitor of VEGFR, is effective at producing
tumour response in clear cell renal cell carcinoma (cRCC), but resistance to therapy is …

Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in …

MJ Edelman, MT Tan, MJ Fidler, RE Sanborn… - Journal of Clinical …, 2015 - ascopubs.org
Purpose Overexpression of COX-2 correlates with advanced stage and worse outcomes in
non–small-cell lung cancer (NSCLC), possibly as a result of elevated levels of COX-2 …

[HTML][HTML] Revisiting the role of COX-2 inhibitor for non-small cell lung cancer

H Yokouchi, K Kanazawa - Translational lung cancer research, 2015 - ncbi.nlm.nih.gov
Accumulating preclinical and clinical studies have shown that cyclooxygenase-2 (COX-2)
inhibitor has some efficacy for non-small cell lung cancer (NSCLC). However, two phase III …

[HTML][HTML] A randomized, placebo-controlled, multicenter, biomarker-selected, Phase 2 study of apricoxib in combination with erlotinib in patients with advanced non …

BJ Gitlitz, E Bernstein, ES Santos, GA Otterson… - Journal of Thoracic …, 2014 - Elsevier
Cyclooxygenase-2 (COX-2) overexpression is associated with a poor prognosis in non–
small-cell lung cancer (NSCLC) and may promote resistance to epidermal growth factor …

[图书][B] Chronic inflammation: molecular pathophysiology, nutritional and therapeutic interventions

S Roy, D Bagchi, SP Raychaudhuri - 2012 - books.google.com
Although acute inflammation is a healthy physiological response indicative of wound
healing, chronic inflammation has been directly implicated in a wide range of degenerative …